SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
____________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): December 15, 2006
Assured
Pharmacy, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-33165
|
98-0233878
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
17935
Sky Park Circle Suite F , Irvine, CA
|
92614
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 949-222-9971
|
___________________________________________________
(Former
name or former address, if changed since last
report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425)
|
| |
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| |
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| |
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
SECTION
5 - Corporate Governance and Management
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
On
December 15, 2006, Robert DelVecchio resigned as our Chief Financial Officer.
On
December 15, 2006, the board of directors appointed Haresh Sheth to fill this
vacancy and act as our Chief Financial Officer. Mr. Sheth resigned his position
as Chief Operating Officer in order to accept the appointment as our Chief
Financial Officer. There was no known disagreement with Messrs. DelVecchio
or
Sheth on any matter relating to our operations, policies or practices.
Mr.
Sheth
was initially appointed as a member of our board of directors in September
2005.
From May 2006 to December 2006, Mr. Sheth acted as our Chief Operating Officer.
Mr. Sheth is a graduate of West Virginia University where he earned an
engineering degree. Since 1991, Mr. Sheth has also acted as President of Janus
Finance Corporation, an asset based finance company. Mr. Sheth joined Mosaic
Capital Advisors LLC in 2004 as their group financial officer.
There
are
no family relationships between Mr. Sheth and any of our directors or executive
officers. Set forth below is a description of all of our transactions or
proposed transactions over the last two years that Mr. Sheth had any material
direct or indirect interest in.
In
May
2006, we entered into an employment agreement with Mr. Sheth in connection
with
his service as Chief Operating Officer and this employment agreement is also
applicable to his service as Chief Financial Officer. Pursuant to the terms
of
the employment agreement, Mr. Sheth receives a base salary of $150,000 and
received options to purchase 1,133,334 shares of common stock exercisable for
a
period of ten years from the date of issuance at the exercise price of $0.60
per
share.
Mosaic
is
a wholly-owned subsidiary of Mosaic Capital Advisors LLC. Mr. Haresh Sheth
who
is a member of our board of directors acts as group financial officer to Mosaic
Capital Advisors LLC.
On
February 23, 2005, we entered into an accounts receivable servicing agreement
and line of credit agreement with Mosaic Financial Services, LLC (“Mosaic”). The
monthly interest rate under this agreement is equal to one and one quarter
percent of the maximum amount of the credit line. This agreement allows us
to
secure financing for inventory purchases over an extended period of time. Under
the terms of the line of credit agreement, the maximum amount that can be drawn
to purchase inventory increased on July 1, 2005 from $500,000 to $700,000.
This
agreement was for a term of one year with a provision to automatically renew
for
another one year period unless either party provides notice to the other of
termination within 180 days prior to the end of the effective term.
Mosaic
provided notice to us of its intent to exercise its right under the line of
credit agreement to convert the $700,000 previously advanced into shares of
our
common stock. On October 24, 2005, our board of directors authorized the
issuance of 2,500,000 shares of our restricted common stock to Mosaic in
accordance with the conversion right provided in the line of credit agreement.
The
price
per
share for the issued shares was $0.28 and the market price on October 24, 2005
was $0.39 per share. The issuance of these shares to Mosaic satisfied our
obligations in full under the accounts receivable servicing agreement and line
of credit agreement.
On
October 31, 2005, we entered into another line of credit agreement (“LOC”) with
Mosaic enabling us to draw a maximum of $1,000,000 to purchase inventory. This
LOC has a one time commitment fee equal to three percent of the initial amount
of the LOC which has a monthly interest rate of 1.5% of the then LOC limit.
These accrued finance charges will be deducted prior to any advances. Under
the
terms of the LOC, Mosaic has a right to convert all or a portion of the
outstanding advances into shares of our common stock where the conversion price
is based on the weighted average closing bid price for our common stock on
the
OTCBB (or such other equivalent market on which our common stock is quoted)
as
for the seven trading days immediately preceding the date the conversion right
is exercised. The conversion price shall not be less than $0.40 or more than
$0.80. Our management anticipates that this LOC will adequately finance
inventory purchases for our existing pharmacies over the next twelve
months. This LOC is secured by substantially all of our
assets.
Mr.
Sheth
acts as President to Janus Financial Services, Inc. (“Janus”). During the
quarterly period ended September 30, 2005, we entered into a consulting
agreement with Janus. Pursuant to the terms of the consulting agreement, we
agreed to pay Janus a monthly consulting fee in the amount of $10,000 for a
period of two years. Under the terms of the consulting agreement, we also issued
Janus options to purchase 1,700,000 shares of our common stock exercisable
at
$0.60 per share. These options become fully vested over three years (566,667
options fully vest on September 29, 2005; 566,667 become fully vested on
September 29, 2006; and 566,666 become fully vested on September 29, 2007)
and
are exercisable until September 29, 2017. On April 30, 2006, the parties by
agreement terminated this consulting agreement and all stock options not vested
were terminated.
Section
8 - Other Events
Item
8.01 Other Events
We
issued
warrants to purchase 3,695,875 shares of our restricted common stock at the
exercise price of $0.60 per share as part of an exempt offering that was
completed on June 17, 2004. On June 15, 2006, our board of directors extended
the termination date of these 3,695,875 warrants from June 17, 2006 to December
31, 2006. On December 15, 2006, our board of directors further extended the
termination date of these 3,695,875 warrants from December 31, 2006 to June
30,
2007.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Assured
Pharmacy, Inc.
/s/
Robert DelVecchio
Robert
DelVecchio
Chief
Executive Officer
Date:
December 21, 2006